Teva Pharmaceutical Industries ROA 2006-2018 | TEVA

Current and historical return on assets (ROA) values for Teva Pharmaceutical Industries (TEVA) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Teva Pharmaceutical Industries ROA for the three months ending September 30, 2018 was 5.01%.
Teva Pharmaceutical Industries ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2018-09-30 $-11.06B $65.06B -16.27%
2018-06-30 $-10.26B $67.03B -14.01%
2018-03-31 $-16.05B $69.18B -20.56%
2017-12-31 $-16.53B $70.62B -19.77%
2017-09-30 $-5.96B $86.08B -6.69%
2017-06-30 $-6.15B $86.36B -6.65%
2017-03-31 $0.08B $91.28B 0.09%
2016-12-31 $0.07B $93.06B 0.09%
2016-09-30 $1.59B $98.75B 2.39%
2016-06-30 $1.35B $57.92B 2.49%
2016-03-31 $1.70B $55.13B 3.26%
2015-12-31 $1.57B $54.23B 3.14%
2015-09-30 $1.78B $48.63B 3.69%
2015-06-30 $2.55B $50.37B 5.35%
2015-03-31 $2.76B $46.95B 5.91%
2014-12-31 $3.06B $46.42B 6.55%
2014-09-30 $2.75B $46.61B 5.85%
2014-06-30 $2.58B $46.73B 5.47%
2014-03-31 $1.38B $46.89B 2.92%
2013-12-31 $1.27B $47.51B 2.66%
2013-09-30 $1.21B $47.85B 2.49%
2013-06-30 $0.42B $47.50B 0.86%
2013-03-31 $1.73B $48.07B 3.52%
2012-12-31 $1.96B $50.61B 3.94%
2012-09-30 $2.15B $49.58B 4.32%
2012-06-30 $3.14B $48.88B 6.59%
2012-03-31 $2.86B $50.47B 6.28%
2011-12-31 $2.76B $50.14B 6.46%
2011-09-30 $3.02B $41.28B 7.62%
2011-06-30 $3.16B $40.16B 8.07%
2011-03-31 $3.38B $39.25B 8.91%
2010-12-31 $3.33B $38.15B 9.10%
2010-09-30 $2.94B $39.04B 8.27%
2010-06-30 $2.54B $35.19B 7.45%
2010-03-31 $2.26B $34.05B 6.78%
2009-12-31 $2.00B $33.81B 6.08%
2009-09-30 $0.93B $33.30B 2.86%
2009-06-30 $0.92B $32.25B 3.01%
2009-03-31 $0.94B $32.24B 3.26%
2008-12-31 $0.64B $32.90B 2.36%
2008-09-30 $1.89B $24.97B 7.72%
2008-06-30 $1.78B $25.02B 7.46%
2008-03-31 $1.76B $24.63B 7.62%
2007-12-31 $1.95B $23.41B 8.80%
2007-09-30 $1.84B $22.50B 8.59%
2007-06-30 $1.92B $21.75B 9.24%
2007-03-31 $1.90B $21.03B 9.38%
2006-12-31 $0.55B $20.47B 2.79%
2006-09-30 $0.39B $20.01B 2.29%
2006-06-30 $0.05B $19.37B 0.35%
2006-03-31 $-0.20B $18.36B -1.64%
2005-12-31 $1.07B $10.39B 10.99%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $23.927B $22.385B
TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $54.860B 9.42
Mylan (MYL) United Kingdom $18.439B 7.59
Bausch Health Cos (BHC) Canada $9.314B 6.74
Dr Reddy's Laboratories (RDY) India $5.645B 22.54
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.589B 4.32
Supernus Pharmaceuticals (SUPN) United States $2.357B 22.33
Amphastar Pharmaceuticals (AMPH) United States $0.978B 106.05
Akorn (AKRX) United States $0.853B 0.00
Homology Medicines (FIXX) United States $0.748B 0.00
Assembly Biosciences (ASMB) United States $0.570B 0.00
CymaBay Therapeutics (CBAY) United States $0.536B 0.00
Corium (CORI) United States $0.458B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.451B 0.00
Voyager Therapeutics (VYGR) United States $0.384B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.315B 0.00
Teligent (TLGT) United States $0.170B 0.00
Sol-Gel Technologies (SLGL) Israel $0.135B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.095B 0.00
Aevi Genomic Medicine (GNMX) United States $0.076B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.053B 0.00
Evoke Pharma (EVOK) United States $0.046B 0.00
Acasti Pharma (ACST) Canada $0.042B 0.00
Agile Therapeutics (AGRX) United States $0.032B 0.00
China Pharma Holdings (CPHI) China $0.016B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.008B 0.00